Cytarabine dosage

The recommended dosage for idarubicin (Idamycin) is 12 mg/m daily for 3 days by intravenous injection in combination with cytarabine. Slow injection with care over 10 to 15 minutes is recommended to avoid extravasation, as with other anthracyclines. 

Two standard dosage schedules are recommended for administration of cytarabine ( cytosar-u, TARABINE PFS, Others) (1) rapid intravenous infusion of 100 mg/nf every 12 hours for 5—7 days or (2) continuous intravenous infusion of 100 to 200 mg/nP daily for 5-7 days. In general, children tolerate higher doses than do adults. Intrathecal doses of 30 mg/m every 4 days have been used to treat meningeal leukemia. The intrathecal administration of 50-70 mg of the liposomal formulation of cytarabine (depocyt) every 2 weeks seems to be equally effective as the every-4-day regimen. Conventional cytarabine is indicated for induction and maintenance of remission in acute nonlymphocytic leukemia and is useful in the treatment of other leukemias, such as ALL AML, and CML in the blast phase. Intrathecal cytarabine is indicated for meningeal leukemia. 

The recommended dosage for idarubicin (IDAMYCIN) is 12 mg/m daily for 3 days by intravenous injection in combination with cytarabine. Daunorubicin (daunomycin, rubidomycin CERUBIDINE, others) is available for intravenous use. The recommended dosage is 30-60 mg/rn daily for 3 days. Total doses of >1000 mg/nP are associated with a high risk of cardiotoxicity. A liposomal formulation of daunorubicin citrate (daunoxome) is indicated for the treatment of acquired immunodeficiency syndrome (AIDS)-related Kaposi s sarcoma. It is given in a dose of 40 mg/m infused over 60 minutes and repeated every 2 weeks. Patients should be advised that the drug may impart a red color to the urine. Daunorubicin is primarily used in the treatment of AML in combination with Ara-C and has largely been replaced by idarubicin. 

Nervous system High-dose cytarabine causes cerebellar toxicity in 10-15% of patients. It should be avoided in patients over 50 years of age and dosage adjustment is required in patients with renal insufficiency, who are at greater risk of nervous system toxicity [15 , 16 ]. 

As part of the diet of rats, chicory inulin inhibited tumor formation (colon, mammary, and lung) and potentiated the cytotoxic effects of various common anticancer drugs at subtherapeutic dosages (cyclophosphamide, cytarabine, doxorubicine, 5-fluoroura-cil, methotrexate, and vincristine). ... 

---